Weight Management
Tesamorelin
Stabilized GHRH analog for metabolic research.
01 — Overview
Overview
A stabilized growth-hormone-releasing factor analog studied for adipose metabolism and lipid-regulation pathways.
Pricing
Available Strengths
Prices are shown per individual vial. For distributor pricing or volume orders, please contact VITRA Bioscience.
Request Wholesale Pricing02 — Science
Mechanism of Action
At the molecular level, Tesamorelin is under investigation for its signaling activity across the pathways associated with growth hormone support. Current preclinical research suggests interactions studied strictly within cellular and in-vitro models, where receptor binding and downstream signaling cascades are characterized to understand its biochemical profile.
03 — Research
Potential Research Applications
Research has explored Tesamorelin across several areas of laboratory investigation. Current preclinical research suggests the following as active domains of scientific study. These represent areas under investigation only and are not statements of clinical outcome.
- Under investigation for lipid metabolism
- Under investigation for adipose research
- Under investigation for endocrine assays
04 — Profile
Scientific Properties
Lyophilized
10 mg
Weight Management
Qualified laboratory use
05 — Data
Technical Specifications
06 — Handling
Storage & Handling
Recommended Storage
Store lyophilized peptide at 2–8°C for short-term handling and at -20°C for long-term storage, protected from light and moisture. Avoid repeated freeze-thaw cycles.
Reconstitution
Reconstitute with bacteriostatic or sterile water for research use. Add diluent slowly against the vial wall and swirl gently until dissolved — do not shake. Once reconstituted, refrigerate at 2–8°C and use within the validated stability window. Do not use if the solution appears cloudy or contains particulates.
Temperature
2–8°C / -20°C long-term
Shelf Life
24 months (lyophilized)
07 — Literature
Research References
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients
Falutz J, et al.
Journal of Clinical Endocrinology & Metabolism · 2010
PMID: 20554713
View PublicationReduction in visceral adiposity is associated with an improved metabolic profile during tesamorelin treatment
Stanley TL, et al.
Clinical Infectious Diseases · 2012
PMID: 22495074
View PublicationScientific references are provided for educational purposes only and do not represent claims regarding any specific VITRA Bioscience product.
09 — Questions
Frequently Asked Questions
No. All VITRA compounds are supplied strictly for laboratory and research use only. They are not for human consumption and are not intended to diagnose, treat, cure or prevent any disease.
VITRA carefully selects research-grade compounds and applies quality-focused sourcing standards. Premium packaging and consistent handling protocols are maintained under controlled manufacturing standards.
Store lyophilized peptide at 2–8°C for short-term handling and at -20°C for long-term storage, protected from light and moisture. Avoid repeated freeze-thaw cycles.
Get in touch
Contact VITRA
Request product information, technical data or research collaboration details for Tesamorelin. Our team responds to qualified inquiries.
Disclaimer
For research use only. Not for human consumption.
Not intended to diagnose, treat, cure or prevent any disease. This product is to be handled exclusively by qualified professionals in an appropriate laboratory setting.